Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders
CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, which will be held in Boston on December 10 – 12. The …